Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of LQ036 Single-Domain Antibody Nebulization Solution in Patients With Poorly Controlled Asthma

What is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people whose asthma is not well controlled. The study will also learn about the safety of LQ036, how the body processes it, and whether the body develops an immune response to it.

What are the main questions?

The most important question is:

• Does LQ036 improve lung function (measured by FEV₁ - the amount of air you can blow out in one second) more than a placebo at Week 12?

Other important questions include:

• Does LQ036 improve lung function at other time points (weeks 1, 2, 4, 8, 16, 20, 24)?
• Does LQ036 reduce asthma attacks (sudden worsening of asthma that needs extra treatment)?
• Does LQ036 help people use less rescue medication (inhaler for quick relief) and have more days without asthma symptoms?
• Does LQ036 improve scores on asthma control and quality of life questionnaires?
• What medical problems do participants have when taking LQ036?

Study Overview

• Status: Recruiting
• Conditions: Asthma
• Intervention / Treatment: Biological: LQ036; Biological: Placebo

Detailed Description

The study includes four periods: a screening period of up to 2 weeks to check eligibility, followed by a 2 week run in period during which all participants take a placebo once daily by nebulizer and record symptoms and rescue medication use. Participants are then randomly assigned to one of three groups for the 24 week treatment period: LQ036 12 mg, LQ036 24 mg, or placebo once daily. For the first 12 weeks, the LQ036 groups are compared with the placebo group; after 12 weeks, those originally on placebo are reassigned to either LQ036 12 mg or 24 mg for the remaining 12 weeks. Throughout the study period, all participants continue their usual asthma controller medicines. A 4 week safety follow up visit occurs after the 24 week treatment to monitor for side effects.

• Study Type: Interventional
• Enrollment (Estimated): 216
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Meng Huang; Phone Number: 86+02120985259; Email: mhuang@novamab.com

Study Locations

• China
  • Shanghai, China
    • Recruiting
    • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    • Contact: Jieming Qu, Principal Investigator; Phone Number: 680801 +86-21-64370045; Email: Jmqu0906@163.com
    • Contact: Wei Tang, Principal Investigator; Phone Number: 680801 +86-21-64370045; Email: Tw10986@rjh.com.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Outpatients, aged 12 to 75 years inclusive, male or female, with body mass index (BMI) between 18 and 30 kg/m² inclusive. For participants aged 12 to 17 years, body weight must be ≥30 kg.
• Diagnosed with bronchial asthma according to the 2025 Global Initiative for Asthma (GINA) guidelines prior to screening, with a documented history of asthma for ≥12 months.
• For at least 3 months prior to screening, the participant has used inhaled corticosteroids (ICS) combined with at least one controller medication, and has maintained a stable treatment regimen and dosage for at least 1 month prior to screening. Low, medium, and high maintenance doses of ICS are defined according to the 2025 GINA guidelines (if multiple nebulized or combined administration methods are used, doses are to be combined).
• At screening, pre-bronchodilator FEV₁ is ≥40% and <80% of the predicted normal value. For participants on low-dose ICS, pre-bronchodilator FEV₁ is ≥40% and <85% of the predicted normal value.
• At screening, Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5.
• At screening, a positive bronchodilator reversibility test (increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL, 15-30 minutes after inhalation of 400 μg salbutamol). If the reversibility test does not reach the positive threshold, one additional test is permitted within 7 days (excluding the day of the initial test). Alternatively, documented evidence of a positive bronchodilator reversibility test within 12 months prior to screening is acceptable.
• At screening, blood eosinophil (EOS) count ≥150 cells/μL and fractional exhaled nitric oxide (FeNO) ≥25 ppb.
• Experienced ≥1 severe exacerbation within the 12 months prior to screening (not required for participants on low-dose ICS).
• Participants fully understand the purpose, nature, methods, and possible adverse reactions of the study, voluntarily agree to participate, and sign the informed consent form before any study procedures begin.
• At randomization, pre-bronchodilator FEV₁ has increased by ≤20% from the screening value, and remains ≥40% and <80% of the predicted normal value (for participants on low-dose ICS, pre-bronchodilator FEV₁ is ≥40% and <85% of the predicted normal value).
• At randomization, ACQ-5 score ≥1.5.
• At randomization, blood EOS count ≥150 cells/μL and FeNO ≥25 ppb.
• During the run-in period, participant compliance with run-in medication and background medication is ≥80% and ≤120%, compliance with daily diary completion is ≥80%, and there are complete data for at least 4 days within the 7 days prior to randomization.

Exclusion Criteria:

• Life-threatening asthma, defined as an asthma episode requiring intubation within 1 year prior to screening or during the run-in period, and/or a history of hypercapnia, respiratory arrest, hypoxic seizures, asthma-related syncopal episodes, etc.
• Experienced a severe asthma exacerbation within 1 month prior to screening.
• History of allergy to biologics, or known hypersensitivity to any component of the investigational product.
• Use of biologics (including but not limited to anti-IgE, anti-IL-5, anti-IL-5 receptor, anti-IL-4/13 receptor, anti-TSLP monoclonal antibodies, etc.) and/or systemic immunosuppressants (including but not limited to methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, penicillamine, sulfasalazine, hydroxychloroquine, azathioprine, cyclophosphamide) for inflammatory diseases within 8 weeks or 5 half-lives (whichever is longer) prior to screening.
• Received intravenous immunoglobulin (IVIG) or allergen-specific immunotherapy (SIT) within 3 months prior to screening.
• Received systemic corticosteroids (excluding topical, ophthalmic, or intranasal corticosteroids), antibiotics, antifungals, antivirals, antiparasitic drugs, non-selective beta-blockers, or herbal medicines with anti-asthmatic effects within 1 month prior to screening or during the run-in period.
• Received live or attenuated vaccine within 3 months prior to screening, or plan to receive live or attenuated vaccine during the study period.
• Underwent bronchial thermoplasty within 12 months prior to screening.
• Underwent major surgery within 8 weeks prior to screening, or plans to undergo surgery requiring general anesthesia or hospitalization for >1 day during the study period.
• In the investigator's judgment, presence of respiratory diseases other than asthma, including but not limited to chronic obstructive pulmonary disease (COPD), asthma-COPD overlap syndrome (ACOS), or any other significant lung disease (e.g., active pneumonia, idiopathic pulmonary fibrosis, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, bronchiectasis, etc.), that may place the participant at undue risk or affect the evaluation of study results.
• Based on imaging and investigator judgment, presence of active tuberculosis or non-tuberculous mycobacterial infection, untreated latent tuberculosis, or history of incompletely treated tuberculosis.
• Active autoimmune disease or autoimmune disease requiring immunosuppressive therapy, such as rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.
• Blood EOS >1500 cells/μL at screening, or other systemic diseases that may cause elevated peripheral blood EOS count (e.g., hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, eosinophilic esophagitis, etc.), which in the investigator's judgment may affect the evaluation of the drug.
• Known or suspected immunodeficiency, including history of invasive opportunistic infection (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) even if resolved; or presence of unusually frequent, recurrent, or prolonged infections suggestive of an immunocompromised state.
• Known parasitic infection, or suspected or high-risk parasitic infection in the investigator's judgment.
• Active infection (e.g., upper respiratory tract infection) within 1 month prior to screening or during the run-in period, or acute infection requiring systemic anti-infective therapy.
• History of lymphoproliferative disease or malignancy (participants with basal cell carcinoma, localized squamous cell carcinoma of the skin, or cervical carcinoma in situ are eligible if they have completed curative treatment and have had no evidence of recurrence for at least 12 months prior to signing informed consent), or other medical history that in the investigator's judgment may affect the evaluation of the drug.
• Presence of any other severe and/or uncontrolled disease or treatment that, in the investigator's judgment, may affect the evaluation of the drug, including but not limited to: severe neurological disease, severe mental disorder, uncontrolled diabetes mellitus, uncontrolled hypertension, major cardiovascular disease, corrected QT interval prolongation (male >450 ms, female >470 ms, Fridericia's formula), or persistent arrhythmia.
• Current smoker or cessation of smoking for <6 months; or former smoker with a smoking history of ≥10 pack-years (pack-years = [cigarettes per day / 20] × years of smoking).
• Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus antibody, or Treponema pallidum antibody at screening (participants with positive HBsAg but HBV-DNA below the lower limit of detection, or positive HCV antibody but HCV-RNA below the lower limit of detection, are eligible).
• Participants with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 × upper limit of normal (ULN), or serum creatinine >1.5 × ULN.
• Pregnant or breastfeeding women; women planning to become pregnant during the study or within 3 months after the end of the study; fertile women or men who, in the investigator's judgment, cannot use medically accepted reliable contraception from signing informed consent until 3 months after the last dose of study drug; positive pregnancy test result at screening or before randomization for fertile women.
• Participation in another clinical study of a drug or device within 3 months prior to signing informed consent, with use of investigational drug/device; or still within the follow-up period of another clinical study or within 5 half-lives of the investigational drug (whichever is longer) at the time of signing informed consent.
• History of blood donation or significant blood loss, blood transfusion, or use of blood products within 3 months prior to screening.
• Known or suspected non-compliance, drug abuse, substance abuse, or alcohol abuse (daily pure alcohol intake >40 g for males, >20 g for females).
• Any condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LQ036 12 mg; LQ036 12 mg solution for nebulization, once daily for 24 weeks.	Biological: LQ036; LQ036 is a single-domain antibody formulated as a solution for nebulization. Participants will self-administer the assigned dose once daily by inhaling the nebulized solution.
Experimental: LQ036 24 mg; LQ036 24 mg solution for nebulization, once daily for 24 weeks.	Biological: LQ036; LQ036 is a single-domain antibody formulated as a solution for nebulization. Participants will self-administer the assigned dose once daily by inhaling the nebulized solution.
Placebo Comparator: Placebo then Re-randomized to LQ036; Placebo solution for nebulization once daily for 12 weeks, followed by re-randomization (1:1) to either LQ036 12 mg or LQ036 24 mg solution for nebulization once daily for an additional 12 weeks.	Biological: LQ036; LQ036 is a single-domain antibody formulated as a solution for nebulization. Participants will self-administer the assigned dose once daily by inhaling the nebulized solution.; Biological: Placebo; Placebo is a look-alike solution for nebulization that contains no active drug. Participants will self-administer the placebo once daily by inhaling the nebulized solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Absolute Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12	Baseline, Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent Change From Baseline in Pre-bronchodilator FEV1 at Week 12		Baseline, Week 12
Absolute and Percent Change From Baseline in Pre-bronchodilator FEV1 at Weeks 1, 2, 4, 8, 16, 20, 24		Baseline, Weeks 1, 2, 4, 8, 16, 20, 24
Absolute and Percent Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) at Weeks 1, 2, 4, 8, 12, 16, 20, 24		Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Absolute and Percent Change From Baseline in Pre-bronchodilator FEV1% Predicted, Forced Vital Capacity (FVC), and Forced Expiratory Flow (FEF25%-75%) at Weeks 1, 2, 4, 8, 12, 16, 20, 24		Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Absolute and Percent Change From Baseline in Post-bronchodilator FEV1 at Weeks 12 and 24		Baseline, Weeks 12, 24
Annualized Rate of Composite Exacerbation (CompEx) Events During the Treatment Period		Baseline up to Week 24
Time to First Composite Exacerbation (CompEx) Event		Baseline up to Week 24
Annualized Rate of Loss of Asthma Control (LOAC) Events During the Treatment Period		Baseline up to Week 24
Time to First Loss of Asthma Control (LOAC) Event		Baseline up to Week 24
Annualized Rate of Severe Exacerbation (SevEx) Events During the Treatment Period (in participants with history of severe exacerbation in past 12 months)		Baseline up to Week 24
Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During the Treatment Period (in participants with history of severe exacerbation in past 12 months)		Baseline up to Week 24
Time to First Severe Exacerbation (SevEx) Event (in participants with history of severe exacerbation in past 12 months)		Baseline up to Week 28
Time to First Severe Exacerbation Event Resulting in Hospitalization or Emergency Room Visit (in participants with history of severe exacerbation in past 12 months)		Baseline up to Week 28
Absolute Change From Baseline in Nighttime Asthma Symptom Scores at Weeks 1, 2, 4, 8, 12, 16, 20, 24	Nighttime asthma symptom score was determined using an AM (ante meridiem) symptom scoring system, which evaluated the participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as follows: 0 = No symptoms; = Symptoms caused one nocturnal awakening (or early awakening);; = Symptoms caused two or more nocturnal awakenings (including early awakening);; = Symptoms caused the participant to be awake for most of the night;; = Symptoms were severe and the participant could not fall asleep at night. Higher scores indicate more severe asthma symptoms. A negative change from baseline represents improvement.	Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Absolute Change From Baseline in Daytime Asthma Symptom Scores at Weeks 1, 2, 4, 8, 12, 16, 20, 24	Daytime asthma symptom score was determined using a PM (post meridiem) symptom scoring system, which evaluated the participant's overall asthma symptoms experienced during the day. It ranged from 0 to 5 as follows: 0 = No symptoms; = Only one short episode of symptoms;; = Two or more short episodes of symptoms;; = Symptoms present most of the time, but did not interfere with daily activities;; = Symptoms present most of the time and interfered with daily activities;; = Symptoms were severe, unable to work or perform daily activities as usual. Higher scores indicate more severe asthma symptoms. A negative change from baseline represents improvement.	Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Absolute Change From Baseline in Average Daily Reliever Medication Use (puffs/day) at Weeks 1, 2, 4, 8, 12, 16, 20, 24		Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Number of Reliever Medication-Free Days During the Treatment Period		Baseline up to Week 24
Absolute Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ[S]) Global Score at Weeks 12 and 24	The Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ[S]) is a 32 item disease specific instrument measuring the functional impairments that are most important to adults with asthma. Each item is scored on a 7 point Likert scale where 1 = maximal impairment and 7 = no impairment. The global score is the mean of all 32 responses, ranging from 1 (severely impaired quality of life) to 7 (not impaired at all). Higher scores indicate better quality of life. A positive change from baseline indicates improvement.	Baseline, Weeks 12, 24
Absolute and Percent Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Each Time Point		Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24
Absolute Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Weeks 1, 2, 4, 8, 12, 16, 20, 24	The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranging from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.	Baseline, Weeks 1, 2, 4, 8, 12, 16, 20, 24

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Measures: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	An adverse event (AE) is any untoward medical occurrence in a participant who received study drug, regardless of causal relationship. TEAEs are defined as AEs that start or worsen on or after the first dose of study drug.	From 2-week placebo run-in period up to Week 28
Safety Measures: Incidence and Severity of Serious Adverse Events (SAEs)	A serious adverse event (SAE) is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.	From Screening up to Week 28
Safety Measures: Number of Participants With Abnormal Vital Signs of Potential Clinical Importance	Vital signs assessments include systolic blood pressure (mmHg), diastolic blood pressure (mmHg), respiratory rate (bmp), heart rate (bpm) and body temperature (℃). Clinically significant abnormalities are determined by the investigator based on pre-defined criteria or medical judgment.	From Screening up to Week 28
Safety Measures: Number of Participants With Clinically Significant Findings on Physical Examination	Physical examination includes assessment of general appearance; skin; head, eyes, ears, nose and throat (HEENT); chest; abdomen; spine; extremities; nervous system; and lymph nodes. Clinically significant findings are determined by the investigator based on pre-defined criteria or medical judgment.	At Screening, Baseline (Week 0), Week 12 and 24.
Safety Measures: Number of Participants With Abnormal Hematology Parameters of Potential Clinical Importance	Hematology assessments include white blood cell count (WBC), white blood cell differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell count (RBC), hemoglobin (Hb), platelet count (PLT), and hematocrit (HCT). Clinically significant abnormalities are determined by the investigator based on pre-defined criteria or medical judgment.	At Screening, Baseline (Week 0), Week 4, 8, 12, 16, 20, 24, 28.
Safety Measures: Number of Participants With Abnormal Clinical Chemistry Parameters of Potential Clinical Importance	Blood chemistry assessments include alanine aminotransferase (ALT); aspartate aminotransferase (AST); total protein (TP); albumin (ALB); total bilirubin (TBIL); direct bilirubin (DBIL); alkaline phosphatase (ALP); gamma-glutamyltransferase (gamma-GGT); serum creatinine (Cr); blood urea (UREA) or blood urea nitrogen (BUN); uric acid (UA); fasting glucose (GLU); triglycerides (TG); total cholesterol (CHOL); low-density lipoprotein cholesterol (LDL-C); high-density lipoprotein cholesterol (HDL-C); lactate dehydrogenase (LDH); and electrolytes (sodium [Na], potassium [K], chloride [Cl]). Clinically significant abnormalities are determined by the investigator based on pre-defined criteria or medical judgment.	At Screening, Baseline (Week 0), at Week 4, 8, 12, 16, 20, 24, 28.
Safety Measures: Number of Participants With Abnormal Urinalysis Parameters of Potential Clinical Importance	Urinalysis assessments include leukocytes, red blood cells, protein, glucose, and urine pH. Clinically significant abnormalities are determined by the investigator based on pre-defined criteria or medical judgment.	At Screening, Baseline (Week 0), Week 4, 12, 24, 28.
Safety Measures: Number of Participants With Potentially Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) Parameters	12-lead ECGs were recorded after participants had rested in a supine position for at least 5 minutes. The following ECG parameters were assessed: heart rate, PR interval, QRS duration, QT interval, and QT interval corrected for heart rate using Fridericia's formula (QTcF, in ms; QTcF = QT/RR^0.33). The clinical significance of any abnormalities was determined by the investigator based on predefined criteria.	At Screening, Baseline (Week 0), Weeks 4, 12, 24 and 28
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LQ036	Maximum observed plasma concentration after nebulized inhalation. Measured in ng/mL.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Time to Maximum Plasma Concentration (Tmax) of LQ036	Time at which Cmax is observed following drug administration. Measured in hours.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Area Under the Plasma Concentration Time Curve From Time 0 to t (AUC(0-t)) of LQ036	Area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration (t). Measured in h·ng/mL.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Apparent Clearance (CL/F) of LQ036	Apparent clearance after nebulized inhalation, calculated as Dose/AUC(0-∞). Measured in L/h.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Apparent Volume of Distribution (Vd/F) of LQ036	Apparent volume of distribution during terminal phase after nebulized inhalation, calculated as (CL/F)/λz. Measured in L.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Terminal Half Life (t1/2) of LQ036	Terminal phase half life calculated as ln(2)/λz. Measured in hours.	Day 1, Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Trough Plasma Concentration (Ctrough) of LQ036	Plasma concentration at the end of a dosing interval just before the next dose. Measured in ng/mL.	Week 2, 4, 12 or early termination
Pharmacokinetics (PK): Last Measurable Plasma Concentration (Clast) of LQ036	Last measurable concentration above the limit of quantification. Measured in ng/mL.	After last dose
Pharmacokinetics (PK): Time of Last Measurable Concentration (Tlast) of LQ036	Time at which Clast is observed after the last dose. Measured in hours.	After last dose
Drug Concentration in Bronchoalveolar Lavage Fluid (if applicable)		Between Week 16 to Week 24
Immunogenicity: Incidence and Titer of Anti-Drug Antibodies (ADA) and Incidence of Neutralizing Antibodies (Nab)		Baseline, Weeks 2, 4, 12, 20, 24, 28
Exploratory outcome: Absolute and Percent Change From Baseline in Induced Sputum Eosinophils (EOS) at Each Time Point (if applicable)		Baseline, Weeks 12, 24

Collaborators and Investigators

• Sponsor: Shanghai Novamab Biopharmaceuticals Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): December 1, 2027

Study Registration Dates

• First Submitted: April 22, 2026
• First Submitted That Met QC Criteria: May 9, 2026
• First Posted (Actual): May 15, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 15, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma
• Other Study ID Numbers: LQSW-LQ036-CN-IIb

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No